Submitter’s Name/Address
Abbott Laboratories
1921 Hurd Drive
Irving, TX 75038

Contact Person
Linda Morris
Senior Regulatory Specialist MS 2-11
Regulatory Affairs
(972) 518-6711
Fax (972) 518-6960

Date of Preparation of this Summary: January 30, 2013

Device Trade or Proprietary Name: ARCHITECT Total Bilirubin

Device Common/Usual Name or Classification Name: Total Bilirubin Reagent

Classification Number/Class: CIG/Class II

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

The assigned 510(k) number is: ___________

Test Description:

ARCHITECT Total Bilirubin is an in vitro diagnostic assay for the quantitative analysis of total bilirubin in human serum or plasma of adults and neonates. Total (conjugated and unconjugated) bilirubin couples with the diazo reagent in the presence of a surfactant to form azobilirubin. The increase in absorbance at 548 nm due to azobilirubin is directly proportional to the total bilirubin concentration.
Substantial Equivalence:

The modified ARCHITECT Total Bilirubin assay is substantially equivalent to the Abbott Total Bilirubin assay (K060574) on the ARCHITECT c8000 Analyzer. These assays yield substantially equivalent Performance Characteristics.

Similarities:

* Both assays are in vitro colorimetric chemical reactions.
* Both assays can be used for the quantitative analysis of total bilirubin in human serum or plasma of adults and neonates.
* Both assays yield similar results.

Differences:

The modified ARCHITECT Total Bilirubin assay has a smaller sample size of 2.6 uL when compared to the Abbott Total Bilirubin (K060574) assay sample size of 4.0 uL.

Intended Use:

The ARCHITECT Total Bilirubin assay is used for the quantitation of total bilirubin in human serum or plasma on the ARCHITECT c8000 system. Measurement of total bilirubin, an organic compound formed during the normal and abnormal destruction of red blood cells, is used in the diagnosis and treatment of liver, hemolytic hematological, and metabolic disorders, including hepatitis and gall bladder block.

A bilirubin (total and unbound) in the neonate test system is a device intended to measure the levels of bilirubin (total and unbound) in the blood (serum) of newborn infants to aid in indicating the risk of bilirubin encephalopathy (kernicterus).
Performance Characteristics:

**Adult Application:** The Total Bilirubin assay method comparison yielded acceptable correlation between the original Total Bilirubin assay and the modified ARCHITECT Total Bilirubin assay. One hundred thirty-eight adult serum samples ranging from 0.11 to 23.96 mg/dL (based on the Total Bilirubin assay results) showed a correlation coefficient of 0.9991, slope of 0.98, and Y-intercept of 0.07 mg/dL using the ARCHITECT c8000 System.

**Neonate Application:** Fifty-four neonate serum samples ranging from 0.94 to 19.05 mg/dL (based on the Roche Total Bilirubin assay on the Hitachi 717 Analyzer assay results) showed a correlation coefficient of 0.9967, slope of 0.99, and Y-intercept of 0.32 mg/dL using the ARCHITECT c8000 System.

Precision studies were conducted using the Total Bilirubin assay. On the ARCHITECT c8000 System, the total %CV for Level 1 is 1.96%, Level 2 is 1.43%, Level 3 is 1.20%, and Level 4 is 1.00%. The ARCHITECT Total Bilirubin assay is linear from 0.1 to 25.0 mg/dL. The functional sensitivity (limit of quantitation) of the ARCHITECT Total Bilirubin assay is ≤ 0.1 mg/dL and the limit of detection (LOD) 0.05 mg/dL.

These data demonstrate the performance of the modified ARCHITECT Total Bilirubin assay is substantially equivalent to the performance of Abbott Total Bilirubin assay.

**Conclusion:**

Based on analytical and clinical studies, the modified ARCHITECT Total Bilirubin assay is substantially equivalent to the performance of the Abbott Total Bilirubin assay (k06574).
Dear Linda Morris:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA’s issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act’s requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for
the Center for Devices and Radiological Health’s (CDRH’s) Office of Compliance. Also, please
note the regulation entitled, “Misbranding by reference to premarket notification” (21CFR Part
807.97). For questions regarding the reporting of adverse events under the MDR regulation (21
CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH’s Office
of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the
Division of Small Manufacturers, International and Consumer Assistance at its toll-free number
(800) 638-2041 or (301) 796-7100 or at its Internet address

Sincerely yours,

Carol C. Benson for

Courtney H. Lias, Ph.D.
Director
Division of Chemistry and Toxicology Devices
Office of In Vitro Diagnostics
and Radiological Health
Center for Devices and Radiological Health

Enclosure
Indications for Use

510(k) Number (if known): k121985

Device Name: ARCHITECT Total Bilirubin

Indications For Use:

The ARCHITECT Total Bilirubin assay is used for the quantitation of total bilirubin in human serum or plasma on the ARCHITECT c8000 system. Measurement of total bilirubin, an organic compound formed during the normal and abnormal destruction of red blood cells, is used in the diagnosis and treatment of liver, hemolytic hematological, and metabolic disorders, including hepatitis and gall bladder block.

A bilirubin (total and unbound) in the neonate test system is a device intended to measure the levels of bilirubin (total and unbound) in the blood (serum) of newborn infants to aid in indicating the risk of bilirubin encephalopathy (kernicterus).

Prescription Use _X_ AND/OR Over-The-Counter Use ___
(Part 21 CFR 801 Subpart D) (21 CFR 801 Subpart C)

(Please do not write below this line-continue on another page of needed)

Concurrence of CDRH, Office of In Vitro Diagnostics and Radiological Health (OIR)

Yung W Chan -S

Division Sign-Off
Office of In Vitro Diagnostics and Radiological Health

510(k)___k121985_